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Treatment of cancer patients with ATP-competitive
inhibitors of BRAF/CRAF kinases surprisingly in-
creases total kinase activity, especially in wild-type
BRAF cells, subverting the desired clinical outcome.
Similar inhibition resistance isobserved for numerous
kinases involving homo/heterodimerization in their
activation cycles. Here, I demonstrate that drug
resistance resulting from kinase dimerization can be
explained using thermodynamic principles. I show
that allosteric regulation by inhibitors is described
by thermodynamic factors that quantify inhibitor-
induced changes in kinase dimerization and the
difference in the drug affinity for a free monomer
versus a dimer harboring one drug molecule. The
analysis extends to kinase homo- and heterodimers,
allows for their symmetric and asymmetric confor-
mations, and predicts how thermodynamic factors
influence dose-response dependencies. I show how
two inhibitors, ineffective on their own, when com-
bined can abolish drug resistance at lower doses
than either inhibitor applied alone. Thus, the mecha-
nistic models suggest ways to overcome resistance
to kinase inhibitors.INTRODUCTION
The human genome encodes over 500 protein kinases (Manning
et al., 2002). Kinase oncogenic mutations are frequently found in
human cancers, many driving the tumor progression and survival
of cancer cells (Holderfield et al., 2014; Thomas et al., 2007).
Pharmaceutical companies race to add new kinase inhibitors
to the ever-increasing number of clinically approved drugs,
and protein kinases are currently the second largest targeted
protein group following G protein-coupled receptors (Cohen,
2002). Although protein kinase inhibitors often show impres-
sive clinical responses, resistance inevitably occurs. Moreover,Cell Repmany kinase inhibitors have unexpected side effects, surpris-
ingly activating signaling pathways by promoting kinase dimer-
ization (Koppikar et al., 2012; Lito et al., 2013).
Homo- and heterodimerization are key events in the physio-
logical and oncogenic activation of numerous kinases, including
receptor tyrosine kinases and multiple cytoplasmic kinases
(Bessman et al., 2014; Dey et al., 2005; Hu et al., 2013; Huang
et al., 2014; Romano et al., 2014; Wang et al., 2012). In
mitogen-activated protein kinase (MAPK) pathways, dimeriza-
tion is essential for the activation of first-tier kinases (MAP3Ks),
including MLK4 and MAP3K11 (Leung and Lassam, 1998).
The MAP3Ks of the extracellular signal-regulated kinase (ERK)
cascade, BRAF and CRAF (RAF-1, gene name), form homo-
and heterodimers as intrinsic steps of their activation cycles
(Freeman et al., 2013; Heidorn et al., 2010; Rushworth et al.,
2006). The discovery of BRAF mutations, such as BRAF600E
(Davies et al., 2002), which lead to oncogenic activation of
BRAF and perpetual ERK activation, has made the MAPK
pathway a primary target for new cancer drugs. Several BRAF
and CRAF inhibitors are undergoing clinical trials or seeing use
in the clinic (Rahman et al., 2014). However, nearly all existing
RAF inhibitors suppress MAPK signaling only in tumors with
mutated BRAF and wild-type RAS. In cells with wild-type
BRAF, these inhibitors paradoxically increase the total CRAF/
BRAF kinase activity due to inhibitor-induced homo- and heter-
odimerization of these kinases (Hatzivassiliou et al., 2010;
Heidorn et al., 2010; Poulikakos et al., 2010). RAF inhibitors
are also ineffective in cells with constitutively active mutant
RAS (Heidorn et al., 2010). Binding to active RAS drives RAF
homo- and heterodimerization by inducing RAF conformational
changes and bringing two RAF molecules into close vicinity at
the plasma membrane (Kholodenko et al., 2000, 2010; Weber
et al., 2001). Since RAF heterodimers have significantly higher
kinase activity than monomers (Garnett et al., 2005; Lavoie and
Therrien, 2015; Rushworth et al., 2006), RAF dimerization is
thought to be a major mechanism causing resistance to RAF
inhibitors in experiments and clinically (Heidorn et al., 2010; Pou-
likakos et al., 2011).
Although all the structural details of how existing ATP-compet-
itive inhibitors induce RAF dimerization are not yet worked out,
current models suggest that these inhibitors stabilize an activeorts 12, 1939–1949, September 22, 2015 ª2015 The Authors 1939
Figure 1. A Core Model of Kinase Dimerization and Inhibitor Binding
(A) Kinetic diagram is shown. R, kinase monomer; I, inhibitor (shown in red).
(B) Dose-response curves. Total kinase activity is normalized by the activity
in the inhibitor’s absence. Inhibitor concentration is normalized by IC50
calculated for kinase monomers, IC50 = K2 (note that in cells under standard
experimental conditions and also in vivo free inhibitor concentration can be
considered as a parameter [Kholodenko et al., 1999]). (Black line) Inhibitor
binding and kinase dimerization are thermodynamically independent events.
(Blue and red lines) Inhibitors show paradoxical kinase activation due to
allosteric effects. Thermodynamic factors, blue line, g = 10, f = 0.05; red, g =
100, f = 0.01.
(C) The dependence of the area under dose-response curves on the ther-
modynamic factor f. The area is calculated for 0 < [I]/IC50 % 10 and
normalized by the area calculated for f = 1; g= 1, which is the area under the
black curve in (B), g = 1 (blue), 2 (green), 10 (red). In (B) and (C), activities of
1940 Cell Reports 12, 1939–1949, September 22, 2015 ª2015 The Akinase conformation and unique side-to-side dimer configura-
tion of the RAF kinase domains (Heidorn et al., 2010; Lavoie
et al., 2013; Wu et al., 2012). Most recent data show that several
sulfonamide RAF inhibitors can disrupt BRAF homodimers;
however, the same inhibitors still markedly induce BRAF-CRAF
heterodimers in cells, a feature that is not yet understood (Theva-
kumaran et al., 2015).
Here I show that inhibitors that increase kinase dimerization
can paradoxically promote overall kinase activity by driving the
formation of catalytically active dimers, carrying a single inhibitor
molecule and a free protomer, with a low affinity for binding a
second inhibitor molecule. The exact dimer affinity for the sec-
ond inhibitor molecule is dictated by the inhibitor and the dimer
structures. Fundamental thermodynamic principles suggest
that this affinity is very different from the inhibitor affinity for a
drug-free dimer. The analysis extends to both homo- and heter-
odimers, allowing for their asymmetric conformations (Bollag
et al., 2010; Hu et al., 2013) and predicting the dose responses
as functions of thermodynamic factors that characterize allo-
steric inhibitor effects. Modeling demonstrates that two struc-
turally different inhibitors can synergize to suppress the activity
of symmetric and asymmetric dimers much more efficiently
than either inhibitor applied alone at considerably larger doses.
The results explain the limited effectiveness of ATP-competitive
inhibitors for numerous kinases that are allosterically regulated
by dimerization, including RAF kinases, Janus kinase 2 (JAK2),
eIF2a kinase PKR-like ER kinase, and the EGFR family members
(Koppikar et al., 2012; Lavoie et al., 2013; Macdonald-Obermann
et al., 2013).
RESULTS
A Core Model of a Symmetric Kinase Dimer and
Allosteric Inhibitor Effects
The aim is to explore how inhibition efficacy depends on
allosteric effects of inhibitors on kinase dimerization. I start
with a core model of kinase interactions with inhibitor molecules,
initially considering a symmetric dimer in which both protomers
have similar conformations. In the inhibitor’s absence, two
kinase monomers (R) form a dimer (RR), which is shown as
step 1 in the kinetic scheme (Figure 1A). The equilibrium dissoci-
ation constant (K1) of this step is assumed to be known from
experimental data (Lavoie et al., 2013; Rajakulendran et al.,
2009). The inhibitor (I) can bind to R, yielding an inhibitor-bound
monomer (RI), which is catalytically inactive (step 2). The disso-
ciation constant (K2) of inhibitor binding to kinase monomers
also is assumed to be known (Bollag et al., 2010; Rahman
et al., 2014). Likewise, I can bind to RR that harbors two I-binding
sites, resulting in a dimer (RIR) that carries a single inhibitor
molecule (step 3, K3). Structural and biochemical data suggest
that RIR dimers are catalytically active, since an inhibitor-bound
protomer can transactivate the inhibitor-free protomer partner
(Lavoie et al., 2014). Partially inhibited RIR dimers also areinhibitor-free dimers are assumed to be ten times higher than monomers
and two times higher than activities of partially inhibited dimers (Rushworth
et al., 2006). The ratio of the kinase abundance (Rtot) and K1 is 0.1. See also
Figure S1.
uthors
formed when an inhibitor-bound monomer RI dimerizes with a
free monomer R (step 4, K4). The subsequent binding of I to
RIR yields a completely inhibited dimer RI-RI (step5, K5), which
also can be formed by two inhibitor-bound, inactive monomers
(step 6, K6).
The kinetic scheme in Figure 1A shows that the dimers RIR
and RI-RI each can be formed in more than one sequence of
reactions, and, therefore, the scheme contains cyclic paths.
Equilibrium constants of reactions along a cycle, in which the
initial and final states are identical, satisfy so-called detailed bal-
ance relationships (see, for example, Ederer and Gilles, 2007;
Hearon, 1953; and Kholodenko et al., 1999). These thermody-
namic restrictions require the product of the equilibrium dissoci-
ation constants (Kds) along a cycle to be equal to 1, as at equilib-
rium the net flux through any cycle vanishes, since the overall
free energy change is zero. Detailed balance relationships,
therefore, decrease the number of independent dissociation
constants. When inhibitor binding and kinase dimerization are in-
dependent events, allKds are readily expressed solely in terms of
dimerization (K1) and inhibitor binding (K2) constants. Taking into
consideration the numbers of free and inhibitor-occupied sites
on kinase dimers, one obtains the following: K3 = K2/2, K4 =
K1/2, K5 = 2K2, and K6 = K1 (see the Supplemental Experimental
Procedures).
Following reports that inhibitors increase dimerization of
numerous kinases (Hatzivassiliou et al., 2010; Heidorn et al.,
2010; Koppikar et al., 2012; Macdonald-Obermann et al.,
2013; Poulikakos et al., 2010; Wu et al., 2012), we now assume
that the inhibitor binding to a monomer facilitates the dimeriza-
tion with a free monomer, yielding the catalytically active RIR
dimer (Lavoie et al., 2014; Rajakulendran et al., 2009). The in-
hibitor-induced change in the dimerization affinity is described
by the facilitation factor (f), which relates the dimerization con-
stants of free monomers (K1) and inhibitor-bound and free
monomers (K4) as follows: K4 = f,K1=2. Clearly, if the facilitation
factor f is less than 1, the RIR dimers are stabilized by the
inhibitor.
Thermodynamic restrictions then require that the first inhibitor
molecule must bind to the kinase dimer (RR) with a dissociation
constant ðK3Þ that is related by the same factor f to the dissoci-
ation constant ðK2Þ of inhibitor binding to a kinase monomer as
follows: K3 = f,K2=2 (see the Supplemental Experimental Proce-
dures for derivations). This thermodynamic relation means that if
the inhibitor increases dimerization ðf < 1Þ, then it binds to an
inhibitor-free dimer with a greater affinity than to a kinase mono-
mer. Further, as shown in the Supplemental Experimental Proce-
dures, thermodynamic restrictions imply that an additional ther-
modynamic factor (g) connects the dissociation constant ðK5Þ of
the binding of the second inhibitor molecule to a partially in-
hibited dimer (RIR) and the dissociation constant ðK2Þ of the
inhibitor binding to a monomer as follows: K5 = 2g,K2. When
g > 1, K5 is greater than 2K2, meaning the second inhibitor mole-
cule binds to partially inhibited dimers less effectively than the
inhibitor binds to a kinase monomer. Finally, the dissociation
constant ðK6Þ of the fully inhibited dimer (RI-RI) is related by
the product of factors f and g to the dissociation constant ðK1Þ
of the inhibitor-free dimer (RR) as follows: K6 = f,g,K1 (see the
Supplemental Experimental Procedures).Cell RepSummarizing, allosteric regulation by an inhibitor can be
described by two independent thermodynamic factors, f that
quantifies the inhibitor-induced increase in dimerization affinity
and g that defines the difference in the affinity of the second
inhibitor molecule for a dimer and the inhibitor affinity for amono-
mer. The g/f ratio accounts for the affinity difference of the first
and second inhibitor molecules binding to a dimer. When this
ratio is less than 1, the binding of the second inhibitor molecule
to a partially inhibited dimer is hindered by allosteric effects.
Thermodynamic Factors Determine the Dose-Response
Curve
For each inhibitor dose, the total kinase activity is the sum of
activities of inhibitor-free monomers, inhibitor-free dimers, and
partially inhibited dimers. The factors f and g determine the ratios
between the concentrations of inhibitor-free, partially inhibited,
and fully inhibited dimers, thereby shaping the dependence of
the total kinase activity on the inhibitor dose, termed the dose-
response curve.
Comparing dose-response curves, it is convenient to ex-
press the inhibitor dose, [I], in terms of the ratio [I]/IC50, where
IC50 is the inhibitor dose that inhibits kinase monomer activity
by 50%. With the [I] increase, the concentrations of inhibitor-
free monomers and dimers decrease, whereas the concentra-
tions of inhibitor-bound monomers and fully inhibited dimers
increase (Figures S1A–S1C). The concentration of partially
inhibited dimers (RIR) initially always rises, as more inhibitor-
bound monomers become available, but with the further [I]
increase it starts declining, since more dimers become fully
inhibited (Hatzivassiliou et al., 2010). Exactly how the concen-
tration dynamics of catalytically active and inactive kinase
forms depend on the ratio [I]/IC50 is determined by the thermo-
dynamic factors (f and g) and the ratio of the kinase abundance
(Rtot) and the dimerization constant K1 (see derivations in
the Supplemental Experimental Procedures). When the ratio
Rtot/K1 is high, kinase dimerization is already saturated in the
inhibitor absence, and the further dimerization affinity increase
induced by the inhibitor does not have an appreciable effect on
the dimer formation.
Thermodynamic Relationships Explain Paradoxical
Kinase Activation by Inhibitors
In the absence of allosteric inhibitor effects, when thermody-
namic factors equal 1, the ratio of the concentrations of all
dimeric and monomeric forms does not change when [I] in-
creases (Figure S1A). The total concentration of signaling-
capable monomers and dimers ([R]+[RR]+[RIR]), and, therefore,
total kinase activity will always decrease with inhibitor increase
(Figures 1B and S1A; see the Supplemental Experimental Proce-
dures for derivations). Thus, we conclude that inhibitors that
do not allosterically regulate kinases always effectively inhibit
kinase activity (provided that their IC50 amounts are in therapeu-
tically reasonable ranges).
When an inhibitor facilitates kinase dimerization ðf < 1
and gR1Þ, the model implies that partially inhibited dimers,
RIR, significantly build up while the formation of completely
inhibited dimers, RI-RI, lags behind (until the inhibitor dose
exceeds the IC50 by orders of magnitude, Figures S1B–S1D).orts 12, 1939–1949, September 22, 2015 ª2015 The Authors 1941
Figure 2. Asymmetric Kinase Dimerization and Allosteric Inhibitor
Effects
(A) Structure of the asymmetric B-RAFV600E homodimer is derived from PDB:
3OG7 (Bollag et al., 2010). A protomer (shown in yellow) is bound to inhibitor
PLX4032 (red).
(B) Kinetic scheme. R1 and R2 are two different protomer conformations in
a dimer.
(C) Effect of the increase in the R1-R2I dimer accumulation on dose responses
in the absence of inhibitor-induced facilitation of R1I-R2 dimer formation, g1 =
0.01 (red line), g1 = 0.05 (blue), g1 = 1 (black). The remaining thermodynamic
factors are as follows: f = 1 and g2 = 10; normalization and other parameters
are the same as in Figure 1. See also Figure S2.
1942 Cell Reports 12, 1939–1949, September 22, 2015 ª2015 The AIn RIR dimers, the inhibitor-bound protomer is inactive, but the
inhibitor-free protomer is allosterically activated by the confor-
mational change, resulting in increased dimer activity (Raja-
kulendran et al., 2009). Since the RIR surge prevails over the
decrease in inhibitor-free dimers (RR) and the RI-RI buildup,
and dimer activity is often considerably higher than monomer
activity (Rushworth et al., 2006), the inhibitor will paradoxically
increase overall kinase activity within a wide concentration range
(if f<1, see the Supplemental Experimental Procedures; Fig-
ure 1B). Only following the [I] increase over its IC50 by orders of
magnitude do most dimers become fully inhibited and the total
kinase activity eventually decreases (Figure 1B). One may
conclude that allosteric kinase regulation by inhibitors, resulting
in thermodynamic factors f < 1 and gR1, can drive primary or
acquired inhibitor resistance.
The roles of thermodynamic factors f and g in shaping the
dose-response curve are different. Sufficiently low f values bring
about paradoxical kinase activation, evenwhen g= 1 (Figure S1E
and derivations in the Supplemental Experimental Procedures).
Notably, the more the inhibitor facilitates dimerization (the lower
is f), the greater the maximum height of a dose-response curve
is, if it exhibits a paradoxical surge in kinase activity (Figure S1D).
On the other hand, even high g values are not sufficient to
produce paradoxical activation when the inhibitor does not
influence dimerization ðf = 1Þ. Yet, kinase activity can still be
resistant to inhibition when g[1, if dimerization is efficient in
the absence of inhibitor (Figure S1F). Therefore, such inhibitors
are ineffective, even if they do not induce paradoxical kinase
activation. For two inhibitors with the same IC50, the decrease
in the net kinase activity will be much steeper for the inhibitor
that does not allosterically regulate the kinase ðf = 1; g= 1Þ
than for an allosteric inhibitor ðf < 1; gR1Þ, regardless if there
is a maximum on the dose-response curve (see Figures 1B,
S1E, and S1F and the Supplemental Experimental Procedures).
Thus, a more objective measure of kinase inhibition and resis-
tance brought about by allosteric drug effects is to compare
the areas under the dose-response curves. As Figure 1C demon-
strates, this area and, therefore, resistance to inhibition, precip-
itously increases with decreasing f (for low f values) and
increasing g. Summarizing, this core thermodynamic model is
able to quantitatively explain paradoxical activity upswings,
which are observed for numerous kinases as the effects of
ATP-competitive inhibitors that allosterically promote kinase
dimerization.
Asymmetric Kinase Homodimer
Recent data demonstrate that dimers of kinases, such as CRAF
or BRAF, are structurally asymmetric (Hu et al., 2013; Bollag
et al., 2010; Figure 2A). Therefore, one next may assume that
monomer (R) dimerization yields an asymmetric dimer (R1R2)
where protomers acquire two different conformations termed
R1 and R2 (step 1 in the kinetic scheme in Figure 2B). This
scheme resembles the kinetic diagram for a symmetric dimer
(Figure 1A), but includes two distinct forms of partially in-
hibited dimers, R1I-R2 and R1-R2I, where an inhibitor is bound
to a protomer in conformations R1 and R2, respectively. Transi-
tions between different dimer conformations can be added to
this scheme (Figure S2A), but, since at the thermodynamicuthors
equilibrium the results remain the same, it is sufficient to analyze
a diagram in Figure 2B.
As for a symmetric dimer, we describe the inhibitor-induced
dimerization increase by the facilitation factor f, which relates
the dimerization constants of free monomers (K1, step 1) and
inhibitor-bound and free monomers (K5, step 5 yielding R1I-R2),
as follows: K5 = f,K1. Then, the same factor f links the inhibitor
affinities for a free monomer (step 2, K2) and a protomer (R1)
within the dimer R1R2 (step 3, K3) as follows: K3 = f,K2 (see the
Supplemental Experimental Procedures). Therefore, if an inhibi-
tor facilitates kinase dimerization ðf < 1Þ, this inhibitor is a more
avid binder of a protomer (R1) in the R1R2 dimer than a free
monomer (R). In contrast, with a symmetric dimer, the affinities
of the first inhibitor molecule for protomer conformations R1
and R2 in the asymmetric dimer are likely to be different. The
difference in the corresponding dissociation constants, K3 and
K4, is described by an additional thermodynamic factor (g1) as
follows: K4 =g1,K3. This factor determines the ratio of the
equilibrium concentrations [R1I-R2] and [R2I-R1], regardless of
whether a transition between these two forms is explicitly incor-
porated in the kinetic scheme. The same factor then relates the
dimerization constants of steps 5 and 6 (yielding R1-R2I) as
follows: K6 =g1,K5. Finally, as for a symmetric dimer, we intro-
duce a thermodynamic factor (g2) that relates two dissociation
constants, K2 and K8, as follows: K8 =g2,K2, where K2 describes
the affinity of the inhibitor binding to a monomer, while K8 repre-
sents the affinity of the second inhibitor molecule binding to the
protomer R1 in a partially inhibited dimer, R1-R2I. The dissocia-
tion constant (K7) of the second inhibitor molecule binding to
the protomer R2 in a partially inhibited dimer (R1I-R2) is as
follows: K7 =g1,g2,K2. Then, the dimerization constants of in-
hibitor-boundmonomers (K9) and freemonomers (K1) are related
by the product of all three thermodynamic factors as follows:
K9 = f,g1,g2,K1 (see the Supplemental Experimental Proce-
dures for derivations). Summarizing, the dimerization constant
K1; the inhibitor affinity for kinase monomers K2; and thermo-
dynamic factors f, g1, and g2 determine all reaction Kds for an
asymmetric dimer.
A distinction between symmetric and asymmetric dimer de-
scriptions is an extra parameter (g1) that quantifies the difference
in the inhibitor affinities for two protomer conformations in an
asymmetric dimer, R1R2. When g1 = 1; all results obtained for a
symmetric dimer are applicable for an asymmetric dimer (such
as shown in Figures 1 and S1 after substituting the factor g for
its analog g2). In particular, in the absence of allosteric inhibitor
influence, the total concentration of asymmetric signaling dimers
and inhibitor-free monomers ([R1R2] + [R1I-R2] + [R1-R2I] + [R])
always decreases with the increasing inhibitor dose, resulting
in a net decrease in kinase activity (Figure S2B). Therefore,
such drugs ðf =g1 =g2 = 1Þwill effectively suppress kinases (Fig-
ure S2C). If the inhibitor promotes kinase dimerization ðf < 1Þ and
has similar affinities for both protomer conformations, then dose-
response curves for an asymmetric dimer are the same as for a
symmetric dimer, and inhibitor-induced paradoxical increases in
kinase activity can be observed (Figure S2C).
When the inhibitor affinities for the protomers R1 and R2 are
different, g1 < 1 implies further inhibitor-induced facilitation of
kinase dimerization that yields the asymmetric R1-R2I dimer,Cell Repwhereas g1 > 1 means that the R1-R2I dimer is less preferably
formed than the R1I-R2 dimer. When there is no inhibitor-induced
facilitation of the R1I-R2 formation ðf = 1Þ, low g1 < 1 values drive
the R1-R2I accumulation, leading to paradoxical kinase acti-
vation (Figure 2C). If the inhibitor efficiently induces R1I-R2
dimerization ðf  1Þ, the elevated R1-R2I accumulation
further increases kinase resistance to inhibition only at high g2
values (Figures S2D–S2F). Under this condition, increasing g1
or g2 similarly decreases inhibitor efficacy, which can be ex-
plained by the fact that the dissociation constants of reactions
yielding fully inhibited dimers include the product of g1 and g2
(Figure S2G).
Summarizing, the formation of both symmetric and asym-
metric kinase dimers causes resistance to allosteric inhibitors
that facilitate dimerization, but there is a richer repertoire of
possibilities allowed by thermodynamics for an asymmetric
dimer. Subsequently given are surprising modeling predictions
that two kinase inhibitors, each ineffective on its own, in combi-
nation can abolish drug resistance by preferably binding to
different protomer conformations.
Overcoming Resistance by Combining Two Inhibitors
that Are Ineffective when Applied Separately
While several reports in the literature confirm that kinase
dimerization conveys resistance to inhibitors, the mechanism is
unknown (Heidorn et al., 2010; Koppikar et al., 2012; Poulikakos
et al., 2011). Here we found that when the dimerization is
enhanced by an allosteric inhibitor, which poorly binds to ki-
nase dimers already carrying one inhibitor molecule, resistance
inevitably occurs. One may conjecture that, if the binding of an
inhibitor to one protomer induces an allosteric change that alters
the conformation of the other, drug-free protomer (Nussinov
et al., 2013), this induced conformation could become a target
for another inhibitor. In this scenario, two structurally different
inhibitors against the same target could synergize to suppress
the kinase activity of the dimer by binding to different conforma-
tions of its protomer constituents. Therefore, I next explore the
inhibition of kinase monomers and dimers by a combination of
two inhibitors, I1 and I2.
A diagram of kinase interactions with two inhibitors includes
four kinetic graphs (Figure S3A). The first two of these graphs
resemble the graph in Figure 2B where I is replaced by I1 or I2,
whereas the remaining two graphs include dimers where proto-
mers R1 and R2 have bound two different inhibitors, namely
R1I1-R2I2 and R1I2-R2I1 (Figure 3A). I assume resistance to
inhibition, considering the worst-case scenario when each inhib-
itor causes paradoxical kinase activation when applied sepa-
rately. This means that the facilitation factors fa and fb are less
than 1 (here and below subscripts ‘‘a’’ and ‘‘b’’ refer to inhibitors
I1 and I2), and the factors g2a and g2b, which describe the binding
of the second inhibitor molecule to partially inhibited dimers, are
about or greater than 1.
Compared with single inhibitors, there are six reactions
yielding dimers harboring two different inhibitors, I1 and I2 (Fig-
ure 3A). Expressing the Kds of these reactions in terms of the
Kds of free monomer (R) dimerization and inhibitor binding to
R requires two additional thermodynamic factors, g3a and g3b
(see the Supplemental Experimental Procedures). The factororts 12, 1939–1949, September 22, 2015 ª2015 The Authors 1943
Figure 3. Effective Kinase Inhibition by a
Combination of Two Inhibitors
(A) Kinetic schemes of kinase dimerization and in-
teractions with two inhibitors, I1 and I2, are shown.
(B) Each inhibitor, I1 (black line) or I2 (blue), when
applied separately causes paradoxical kinase
activation. However, even low doses of I2 abolish
resistance when taken in combination with an IC50
dose of I1, which is ineffective on its own (red line).
IC50 = K2a for I1; IC50 = K2b for I2.
(C) Synergy between inhibitors is shown by lines of
constant inhibition (termed Loewe isoboles).
Thermodynamic factors for (B) and (C) are as fol-
lows: fa = 0.01, fb = 0.005, g1a = 2, g1b = 5, g2a = 10,
g2b = 20, g3a = 0.01, and g3b = 10. The remaining
parameters and normalization are the same as in
Figure 1. See also Figure S3.g3a quantifies the difference in the Kds of I1 binding to a free
monomer R versus to the protomer R1 in the R1-R2I2 dimer
(yielding R1I1-R2I2). If I1 preferably binds to the conformation R1
in the R1-R2I2 dimer, then g3a is less than 1. Likewise, the factor
g3b describes the difference in the Kds of I2 binding to R versus to
R1 in the R1-R2I1 dimer (yielding R1I2-R2I1). The dissociation con-
stants of alternative reactions that yield fully inhibited dimers,
R1I1-R2I2 or R1I2-R2I1, include the products g1b,g3a or g1a,g3b
(see the Supplemental Experimental Procedures for derivations).
Therefore, if one or both factors g3a and g3b are less than 1, the
formation of fully inhibited dimers is prompted by combining two
inhibitors.
Figure 3B shows that kinase activity is resistant to I1 and I2
applied separately (black and blue lines). However, when I2 is
applied in addition to the I1 dose, which by itself only activates
the kinase, the combination of I1 and I2 effectively inhibits kinase
activity, thus overcoming resistance (red line). Similarly, there is
no resistance if I1 is applied on top of the I2 dose that by itself
only activates the kinase (Figure S3B). Interactions between
two inhibitors or drugs also can be assessed by plotting inhibi-
tion effects across a two-dimensional range of drug doses,
thereby creating a response surface (Keith et al., 2005; Yeh
et al., 2009). Lines of constant inhibition on response surfaces
are termed Loewe isoboles (Greco et al., 1995). For non-inter-
acting drugs, Loewe isoboles are straight lines (Figure S3C;
see the Supplemental Experimental Procedures where the con-
straints on thermodynamic factors defining two non-interacting
inhibitors are derived). If two drugs synergize, Loewe isoboles
are concave, since lesser drug doses result in the same inhibi-
tory effect that these drugs would achieve if they would not
interact. Convex isoboles indicate drug antagonism, because1944 Cell Reports 12, 1939–1949, September 22, 2015 ª2015 The Authorsdrug combinations require increased
doses to achieve the same inhibition.
Figure 3C shows Loewe isoboles on the
plane of the I1 and I2 doses normalized by
IC50 for each inhibitor. We see that if bind-
ing of the second inhibitor molecule to a
dimer is facilitated when two inhibitors
are applied together compared to individ-
ual inhibitors, this leads to a remarkablesynergy between inhibitors (Figure 3C). Importantly, two inhibi-
tors that are individually ineffective, in combination can abolish
inhibition resistance across a wide range of thermodynamic fac-
tors, provided that dimers bind two different inhibitors more
effectively than two molecules of either inhibitor (Figures S3D
and S3E). If the formation of dimers carrying two molecules of
different inhibitors is impeded, these drugs show antagonism
(Figure S3F).
Allosteric Regulation of BRAF-CRAF Heterodimers by
ATP-Competitive Inhibitors
Next is an analysis of the paradoxical effect of enhancing the to-
tal RAF activity by RAF inhibitors, which remains a significant
problem in clinic (Rahman et al., 2014). To that end, I develop
a core model describing BRAF-CRAF heterodimerization and in-
teractionswith inhibitors. A kinetic scheme of themodel is shown
in Figure 4A (where BRAF and CRAF are denoted by B and C,
respectively). Here, step 1 is heterodimerization of inhibitor-
free BRAF and CRAF monomers with the dissociation constant
K1. The inhibitor I binds to BRAF and CRAF monomers (steps
2 and 3) with similar or different affinities, characterized by the
dissociation constants, K2 and K3. The ratio of these constants,
K3=K2, determines the inhibitor specificity. If the ratio is around 1,
the inhibitor is termed a pan-RAF inhibitor, if it is much greater
than 1, the inhibitor is BRAF specific.
ATP-competitive inhibitors stabilize an active RAF kinase
domain conformation, prompting side-to-side dimerization of
kinase domains (Lavoie and Therrien, 2015). As above, this is
quantified by the facilitation factor f that relates two dimerization
constants, K1 and K6, of inhibitor-free monomers (step 1) and
inhibitor-bound BRAF (BI) and free CRAF (step 6), such that
Figure 4. AModel of BRAF and CRAF Heter-
odimerization and Inhibitor Binding
(A) Kinetic diagram of BRAF and CRAF dimeriza-
tion and inhibitor binding is shown.
(B) Sensitivity of dose-response curves to changes
in inhibitor specificity for BRAF. Total kinase ac-
tivity is normalized as in Figure 1; inhibitor dose is
normalized by IC50 for BRAF monomers, IC50 = K2.
(C) Dependence of the total concentration of active
heterodimers ([BC] + [BI-C] + [B-CI]) on the inhibi-
tor dose for different inhibitor specificities. Total
active heterodimer concentration is normalized by
its value with no inhibitor. Parameter values for (B)
and (C) are as follows: g1 = 1, g2 = 10, f = 0.03, K3/
K2 = 1 (red curves), 5 (blue), and 25 (black).
Total concentrations of BRAF and CRAF are equal
(RAFtot), RAFtot /K1 = 0.1. Inhibitor-free hetero-
dimers are twice as active as partially inhibited
heterodimers and 15 times as active as BRAF
monomers, and a BRAF monomer is twice as
active as a CRAF monomer (Rushworth et al.,
2006). See also Figure S4.K6 = f,K1. Thermodynamic restrictions then require that the
dissociation constants, K4 of inhibitor binding to a BRAF proto-
mer in a BC heterodimer (step 4) and K2 of inhibitor binding to
a free BRAF monomer, must be related by the same facilitation
factor f, such that K4 = f,K2 (see the Supplemental Experimental
Procedures).
Step 5 yields another form of partially active heterodimer,
B-CI, where the inhibitor is bound to a CRAF protomer. Accord-
ingly, an additional thermodynamic factor, g1, is required
(together with f) to relate the free energies of inhibitor binding
to a CRAF protomer in a BC heterodimer (step 5) versus a
CRAF monomer, such that K5 = f,g1,K3. The same two factors
connect two dimerization constants, K1 and K7, of inhibitor-
free monomers (step 1) and inhibitor-bound CRAF (CI) and free
BRAF (step 7) as follows: K7 = f,g1,K1 (see the Supplemental
Experimental Procedures). Similarly as to asymmetric homo-
dimers, another thermodynamic factor (g2) relates two dissocia-
tion constants, K9 of inhibitor binding to a BRAF protomer in a
partially inhibited dimer (B-CI) and K2 of inhibitor binding to a
monomeric BRAF, as follows: K9 =g2,K2. Then, the dissociation
constant (K8) of inhibitor binding to aCRAF protomer in a partially
inhibited dimer (BI-C) is as follows: K8 =g1,g2,K3. Thus,
enhancement of BRAF-CRAF dimerization by a drug leads to
its increased binding to one protomer in BC dimers, whereas
the free protomer can be left with a much lesser affinity for
this drug.
Finally, the dimerization constant for two inhibitor-bound
monomers BI and CI (K10) is related by the product of factors f,Cell Reports 12, 1939–1949, Sepg1, and g2 to the dimerization constant
of free BRAF and CRAF monomers as
follows: K10 = f,g1,g2,K1 (see the Sup-
plemental Experimental Procedures for
derivation). Summarizing, the Kds of all
dimerization and inhibitor-binding reac-
tions are expressed in terms of the disso-
ciation constants of BRAF and CRAFdimerization; inhibitor binding to free BRAF and CRAF mono-
mers; and thermodynamic factors f, g1, and g2.
Dose-Response Curves Show Resistance to Single
Inhibitors that Promote Dimerization
If an inhibitor promotes dimerization, the model suggests that
this inhibitor drives the formation of catalytically active BI-C
and B-CI heterodimers, while the accumulation of completely in-
hibited BI-CI dimers lags behind (Figure S4A). The heterodimer
activity is estimated to be 10–20 times higher than the activity
of BRAF and CRAF monomers/homodimers (Freeman et al.,
2013; Rushworth et al., 2006; see the Supplemental Experi-
mental Procedures. As a result, dose-response curves show
paradoxical increases in the total RAF kinase activity (Figure 4B),
resembling the behavior of the total concentrations of catalyti-
cally active heterodimers (Figure 4C). Simulations suggest that
specific BRAF inhibitors, which have higher affinity for BRAF
versus CRAF, instigate paradoxical activation more significantly
than pan-RAF inhibitors (provided that these inhibitors equally
facilitate BRAF-CRAF dimerization; Figures 4B, 4C, and S4A).
These results are consistent with a recent report that pan-RAF
inhibitors are more effective than specific BRAF inhibitors in
melanoma patients who have developed resistance (Girotti
et al., 2015). One may conclude that inhibitor-induced increase
in RAF dimerization and weak inhibitor affinities for partially
inhibited heterodimers drive inhibition resistance, preventing
kinase activity suppression at therapeutically relevant inhib-
itor doses (Figures S4B–S4D). Finally, since kinase activity oftember 22, 2015 ª2015 The Authors 1945
Figure 5. A Combination of Two Individually
Ineffective Inhibitors Can Abolish BRAF/
CRAF Inhibition Resistance
(A) Kinetic schemes of BRAF and CRAF hetero-
dimerization and interactions with two inhibitors, I1
and I2. Active monomers and dimers are denoted
by the red asterisks.
(B) Each inhibitor, I1 (black line) and I2 (blue), when
applied separately causes paradoxical kinase
activation. When taken in combination with an IC50
dose of I2, which is ineffective on its own, even low
doses of I1 abolish resistance (red line). IC50 = K2a
for I1; IC50 = K2b for I2.
(C) Loewe isoboles show synergy between these
two inhibitors. Thermodynamic factors for (B) and
(C) are as follows: fa = 0.01, fb = 0.1, g1a = 1, g1b =
0.1, g2a = 50, g2b = 5, g3a = 0.5, and g3b = 0.05. The
remaining parameters and normalization are the
same as in Figure 4. See also Figure S5.heterodimers is significantly greater than homodimer activities
(Garnett et al., 2005; Rushworth et al., 2006), the results obtained
with this model are applicable to the cellular BRAF and RAF
system, where both homodimers and heterodimers are formed
under physiological conditions.
A Combination of Two Inhibitors Can Abolish
BRAF-CRAF Inhibition Resistance
The difference in the BRAF-CRAF dimer affinities for the
first and second inhibitor molecules depends on both the
dimer and inhibitor structures and allosteric effects induced
by the first inhibitor molecule. Allosteric interactions between
inhibitors (Nussinov et al., 2013) may result in the tighter
binding of two molecules of different inhibitors than two mole-
cules of either inhibitor to a BRAF-CRAF dimer. Consequently,
these two inhibitors can synergistically suppress BRAF and
CRAF signaling. I analyzed this hypothesis using our core
model of the BRAF and CRAF system with two different RAF
inhibitors.1946 Cell Reports 12, 1939–1949, September 22, 2015 ª2015 The AuthorsWhen two inhibitors (I1 and I2) are
applied together, each inhibitor can bind
separately and also in combination with
another inhibitor, as shown by four ki-
netic graphs in Figures 5A and S5A. Two
of these graphs present reactions that
involve only I1 or I2, whereas the remaining
two graphs include BRAF and CRAF
heterodimers that have bound different
inhibitors (BI1-CI2 or BI2-CI1). As in the
case with asymmetric homodimers, two
additional thermodynamic factors, g3a
and g3b, are needed to express the Kds
of I1 binding to B-CI2 (g3a) and I2 binding
to B-CI1 (g3b) in terms of the Kds of I1
and I2 binding to free BRAF and CRAF
monomers (see the Supplemental Exper-
imental Procedures for derivations).
I showed that pan-RAF inhibitors
suppress total kinase activity more effi-ciently than specific BRAF (or CRAF) inhibitors (Figures 4B,
4C, and S4A). Therefore, to analyze if a combination of two
drugs can surmount resistance, consider an unfavorable situ-
ation when each pan-RAF inhibitor (I1 and I2) causes paradox-
ical kinase activation, when applied separately. One may
conjecture that if the I1 affinity for B-CI2 heterodimer is higher
than for B-CI1 heterodimer, due to allosteric influence of I2,
there will be synergy between these two inhibitors. Testing
this hypothesis, I found that, in this case, even low doses of
I1 already abolish resistance when taken in combination with
an IC50 dose of I2, which is ineffective on its own (Figure 5B).
Likewise, the synergy will be observed if the I2 affinity for B-CI1
heterodimer is higher than for B-CI2 heterodimer, due to allo-
steric influence of I1 (Figure S5B). The analysis of Loewe
isoboles demonstrates that synergy between two different in-
hibitors occurs in a wide range of kinetic constants and also
extends to a combination of two specific BRAF inhibitors or
a specific BRAF and a pan-RAF inhibitor (Figures 5C, S5D,
and S5E). However, if binding of one inhibitor to a heterodimer
hinders binding of the other inhibitor, these two RAF inhibitors
can show antagonism (Figure S5F). In this case, each inhibitor
and their combination are ineffective. Instructively, at some
values of thermodynamic factors, two drugs can show antag-
onism, synergy, or independence in different dose ranges
(Figure S5G).
DISCUSSION
Discovered more than a decade ago, the paradoxical activa-
tion of the MAPK pathway by ATP-competitive RAF inhibitors
caught the scientific community by surprise (Hall-Jackson
et al., 1999). It took another 10 years to recognize that failure
of oncogenic BRAF600E inhibitors to suppress proliferative
signaling in patients with mutant RAS is related to RAS-depen-
dent heterodimerization of BRAF and CRAF. In these dimers,
kinase-dead or inhibited BRAF allosterically activates CRAF,
driving MAPK signaling (Hatzivassiliou et al., 2010; Heidorn
et al., 2010; Wan et al., 2004). Paradoxical activation of
mitogenic signaling by RAF inhibitors causes both drug
resistance and clinical side effects, including frequent inci-
dence of keratoacanthomas and squamous cell carcinomas
(Rahman et al., 2014). This highlights the necessity of quanti-
tative understanding of drug-induced signaling and genotyp-
ing tumors before using these drugs in patients. A similar
cautioning is echoed by resistance of JAK-STAT signaling to
JAK ATP-competitive inhibitors induced by homo- and heter-
odimerization of JAK kinases (Brooks et al., 2014; Koppikar
et al., 2012).
Here I presented quantitative analysis of allosteric effects of
ATP-competitive inhibitors on kinase dimerization and total
activity. I showed that, in addition to the degree of promoting
dimerization by an inhibitor, other thermodynamic factors,
such as the drug affinity difference for protomers in asym-
metric dimers or heterodimers and the inhibitor affinity for
dimers already carrying single drug molecules, can drive inhi-
bition resistance. My analysis suggests that upon dimerization
the affinity of drug binding to one protomer increases, but then
the second, unoccupied protomer experiences a steep reduc-
tion in affinity. This leads to an accumulation of kinase dimers
that have one protomer bound to drug and the other not. As
the drug-bound protomer allosterically activates the free
protomer, this constellation brings about very high signaling
activity upon inhibitor addition. In the Protein Data Bank
(PDB), there are structures of BRAF and CRAF dimers co-
crystallized with different RAF inhibitors, including PLX4032.
Although during the co-crystallization the inhibitor concentra-
tions were extremely high, several co-crystallized dimer struc-
tures show only one of the two protomers bound to inhibitor
(Bollag et al., 2010). This suggests that the dimer affinity for
the second inhibitor molecule precipitously drops compared
to the affinity for the first inhibitor molecule, in line with my
results.
Central to this analysis was a principle of microscopic
reversibility and detailed balance relationships between the
equilibrium dissociation constants. Resulting constraints on
the concentrations of inhibitor-free and inhibitor-bound ki-
nase monomers and homo- and heterodimers determine theCell Reptotal activity response to drug. In cells, kinase dimerization,
as well as G protein-coupled receptor dimerization, usually
is followed by kinetically irreversible steps with large free en-
ergy changes, such as phosphorylation or GTP hydrolysis.
At first glance, these energy-generating steps suggest that
signaling networks are not constrained by the detailed balance
equations. However, this assertion misses the point that com-
plex signaling networks with kinetically irreversible reactions
contain subnetworks, in which inhibitor (or modulator) binding
occurs without changes in the phosphorylation status of
protein monomers and dimers. The corresponding free energy
changes equal zero along cyclic reaction routes. Although
being embedded in larger reaction networks where the net
phosphorylation and dephosphorylation fluxes may not be
zero, signaling subnetworks with no changes in the phos-
phorylation status practically always obey the detailed bal-
ance relationships (Colquhoun et al., 2004; Ederer and Gilles,
2007; Yang et al., 2006). For instance, reactions of inhibitor
binding to phosphorylated protein monomers and dimers
generate another reaction subnetwork in addition to the
analyzed above subnetwork containing unphosphorylated ki-
nase forms. This subnetwork is again restricted by the detailed
balance equations. Of course, a cyclic reaction path that
includes kinetically irreversible (de)phosphorylation reactions
is accompanied by the free energy change, and the detailed
balance relationships do not apply (Kholodenko et al., 1999;
Markevich et al., 2004).
My mechanistic models show that pan-RAF inhibitors sup-
press BRAF/CRAF activity more effectively than specific RAF
inhibitors. These models also suggest ways to surmount inhi-
bition resistance by the combined action of two RAF inhibitors.
For instance, if a specific inhibitor of oncogenic BRAF600E
induces paradoxical ERK activation in wild-type cells, a com-
bination with a pan-RAF inhibitor might be more effective. I
demonstrate that even if each inhibitor is ineffective individu-
ally, but allosteric interaction of one inhibitor with a kinase
dimer facilitates the binding of another inhibitor to this dimer,
this inhibitor combination abolishes resistance (Figures 3
and 5). Thus, a choice of effective inhibitor combination can
be aimed at selecting inhibitors that preferably associate
with different protomer conformations in an asymmetric kinase
dimer.
EXPERIMENTAL PROCEDURES
Reaction lists for all models and thermodynamic relationships between
the equilibrium dissociation constants (Kds) are given in the Supple-
mental Experimental Procedures (Reaction Lists S1–S5). Derivations
of these relationships and the properties of dose-response curves are
presented in the Supplemental Experimental Procedures. Equilibrium
concentrations of different forms of kinase monomers and dimers are
derived in the Supplemental Experimental Procedures. Numerically, all
concentrations and total kinase activities are calculated with Mathe-
matica software from equations given in the Supplemental Experimental
Procedures.
Here a typical derivation of the relationships between the Kds is given for a
model of the allosteric regulation of BRAF–CRAF heterodimers by an inhibitor
(Figure 4A). We first identify all cyclic paths in the kinetic scheme presented in
Figure 4A. Equating the total free energy change along each cyclic path to
zero, we obtain the following relationships between the free energy changesorts 12, 1939–1949, September 22, 2015 ª2015 The Authors 1947
ðDGiÞ of individual reactions (index i is the reaction number in the kinetic
scheme; Figure 4A):
DG1 +DG4 +DG8 = DG1 +DG5 +DG9 =DG2 +DG6 +DG8
=DG3 +DG7 +DG9 =DG2 +DG3 +DG10:
(Equation 1)
The Gibbs free energy change is directly related to the equilibrium dissociation
constant of a reaction,
DG=RT,lnðKd=c0Þ; (Equation 2)
whereR is the gas constant, T is temperature, and c0 has a numerical value of 1
and units that are the reciprocal of the units of the concentration quotient to
make theKd=c0 ratio dimensionless. Equation 2 shows that linear relationships
(Equation 1) between the free energy changes are equivalent to constraints on
the products of the Kds of the corresponding reactions.
The Kds of inhibitor binding to BRAF (K2) and CRAF (K3) monomers and
dimerization (K1) of inhibitor-free BRAF and CRAF monomers are assumed
to be known (see the text). Since the matrix of the linear equation sys-
tem (Equation 1) has rank 4, there are four independent linear relation-
ships between three known ðDG1;DG2; and DG3Þ and seven unknown
ðDG4;DG5;DG6;DG7;DG8;DG9 ; and DG10Þ free energy changes. Conse-
quently, three independent thermodynamic factors are required to express
seven unknown Kds in terms of K1, K2, and K3. I have introduced these factors
as (1) the facilitation factor f that quantifies the extent of promoting dimerization
by an inhibitor, K6 = f,K1; (2) the factor g1 that determines the difference in the
affinities of the first inhibitor molecule for two protomers (BRAF and CRAF) in
the BC heterodimer, K5=K4 =g1,K3=K2; and (3) the factor g2 that defines the
difference in the affinity of the second inhibitor molecule for a BRAF protomer
in a B-CI dimer and the inhibitor affinity for BRAFmonomers,K9 =g2,K2. Using
these three relationships and solving linear Equation 1, we arrive at the expres-
sions of all remainingKds in terms of K1, K2, and K3 and thermodynamic factors
f, g1, and g2 (see the text and Reaction List 4 in the Supplemental Experimental
Procedures). According to Equation 2, the parameters f, g1, and g2 directly
relate to the differences in the Gibbs free energy changes of the corresponding
reactions, and this explains the logic of referring to these parameters as ther-
modynamic factors.SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures
and five figures and can be found with this article online at http://dx.doi.org/
10.1016/j.celrep.2015.08.014.
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